Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRXGet Rating) in a report issued on Saturday. The brokerage set a “sell” rating on the stock.

Separately, Oppenheimer reissued an “outperform” rating and issued a $14.00 price target on shares of Moleculin Biotech in a research report on Monday, July 18th.

Moleculin Biotech Trading Down 0.6 %

Shares of NASDAQ:MBRX opened at $1.70 on Friday. The stock has a market capitalization of $48.58 million, a PE ratio of -2.70 and a beta of 1.78. Moleculin Biotech has a 1 year low of $1.02 and a 1 year high of $3.20. The firm has a fifty day moving average price of $1.58 and a 200 day moving average price of $1.55.

Moleculin Biotech (NASDAQ:MBRXGet Rating) last released its earnings results on Wednesday, May 11th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.03). On average, sell-side analysts forecast that Moleculin Biotech will post -1.01 earnings per share for the current fiscal year.

Institutional Trading of Moleculin Biotech

Several hedge funds and other institutional investors have recently bought and sold shares of MBRX. Sigma Planning Corp acquired a new stake in Moleculin Biotech in the 4th quarter worth about $80,000. Renaissance Technologies LLC increased its position in Moleculin Biotech by 79.3% during the 1st quarter. Renaissance Technologies LLC now owns 59,900 shares of the company’s stock worth $107,000 after purchasing an additional 26,500 shares in the last quarter. Walker Asset Management LLC bought a new stake in Moleculin Biotech during the 2nd quarter worth approximately $32,000. Finally, State Street Corp grew its holdings in Moleculin Biotech by 19.2% during the 1st quarter. State Street Corp now owns 71,397 shares of the company’s stock worth $127,000 after acquiring an additional 11,497 shares during the last quarter. Institutional investors and hedge funds own 10.57% of the company’s stock.

Moleculin Biotech Company Profile

(Get Rating)

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.